Potential role of the microvasculature in progression of heart failure

American Journal of Cardiology

Volumn 84, Issue 4 SUPPL. 1, 1999, Pages 23-26

  Liu, Peter P ^a   Mak, Susanna ^a   Stewart, Duncan J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ENDOTHELIN; NITRIC OXIDE; CALCIUM CHANNEL BLOCKING AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NOS2A PROTEIN, HUMAN;

ARTICLE; ENDOTHELIUM; HEART DILATATION; HEART FAILURE; HEART MUSCLE PERFUSION; HEART VENTRICLE REMODELING; HUMAN; MICROVASCULATURE; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOMYOPATHY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HAMSTER; HEART MUSCLE CELL; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; ANIMAL; CONGESTIVE CARDIOMYOPATHY; CORONARY BLOOD VESSEL; DISEASE COURSE; DISEASE MODEL; HEART MUSCLE; METABOLISM; MICROCIRCULATION; PATHOLOGY; PROSPECTIVE STUDY; REVIEW;

AMLODIPINE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CARDIOMYOPATHY, DILATED; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELINS; HUMANS; MICROCIRCULATION; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 0032821916     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00361-6     Document Type: Article

References (38)

1. Orenstein T., Parker T., Wen W.H., Goodman J.M., Wee L., Butany J., McLaughlin R.P., Liu P. Favorable left ventricular remodeling following large myocardial infarction by exercise training effect on ventricular morphology and gene expression . J Clin Invest. 96:1995;858-866.
2. Izumo S., Lompre A.M., Matsuoka R., Koren G., Schwartz K., Nadal-Ginard B., Mahdavi V. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. J Clin Invest. 79:1987;970-977.
3. 1-adrenergic induction of the hypertrophic phenotype in cardiac myocytes. J Biol Chem. 272:1997;31915-31921.
4. Gerdes A.M., Capasso J.M. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol. 27:1995;849-856.
5. Dixon I.M., Ju H., Jassal D.S., Peterson D.J. Effect of ramipril and losartan on collagen expresson in right and left heart after myocardial infarction. Mol Cell Biochem. 165:1996;31-45.
6. Lee J.K., Zaidi S.H.E., Liu P., Dawood F., Cheah A.Y.L., Wen W.H., Saiki Y., Rabinovitch M. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function following experimental murine myocarditis. Nature Med. 4:1998;1383-1391.
7. Tyagi S.C., Kuman S.G., Alla S.R., Reddy H.K., Voelker D.J., Janicki J.S. Extracellular matrix regulation of metalloproteinase and antiproteinase in human heart fibroblast cells. J Cell Physiol. 167:1996;137-147.
8. Gunja-Smith Z., Morales A.R., Romanelli R., Woessner J.F.J. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy role of metalloproteinases and pyridinoline cross-links . Am J Pathol. 148:1996;1345-1350.
9. Brener D.A., O'Hara M., Angel P., Chojkier M., Karin M. Prolonged activation of jun and collagenase genes by tumor necrosis factor-alpha. Nature. 337:1989;661-663.
10. Tyagi S.C., Kumar S., Borders S. Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells. J Cell Biochem. 61:1996;139-151.
11. Liu P. The path to cardiomyopathy cycles of injury, repair and maladaptation . Curr Opin Cardiol. 11:1996;291-292.
12. Factor S.M., Minase T., Cho S., Fein F., Capasso J.M., Sonnenblick E.H. Coronary microvascular abnormalities in the hypertensive-diabetic rat a primary cause of cardiomyopathy? Am J Pathol. 116:1984;9-20.
13. Factor S.M., Okun E.M., Minase T. Capillary microaneurysms in the human diabetic heart. N Engl J Med. 302:1980;384-388.
14. Factor S.M., Minase T., Cho S., Dominitz R., Sonnenblick E.H. Microvascular spasm in the cardiomyopathic Syrian hamster a preventable cause of focal myocardial necrosis . Circulation. 66:1982;342-354.
15. Factor S.M., Cho S., Wittner M., Tanowitz H. Abnormalities of the coronary microcirculation in acute murine Chagas' disease. Am J Trop Med Hyg. 34:1985;246-253.
16. Dong R., Liu P., Wee L., Butany J., Sole M. Verapamil attenuates the histological features of murine myocarditis. J Clin Invest. 90:1992;2022-2030.
17. Morris S.A., Weiss L.M., Factor S.M., Bilezikian J.P., Tanowitz H., Wittner M. Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice. J Am Coll Cardiol. 14:1989;782-789.
18. Sole M.J., Liu P. Viral myocarditis developing a paradigm for pathogenesis and treatment of dilated cardiomyopathy . J Am Coll Cardiol. 22:1993;99-105.
19. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
20. Ungureanu-Longrois D., Balligand J.L., Kelly R.A., Smith T.W. Myocardial contractile dysfunction in the systemic inflammatory response syndrome role of a cytokine-inducible nitric oxide synthase in cardiac myocytes . J Mol Cell Cardiol. 27:1995;155-167.
21. Balligand J.L., Kelly R.A., Marsden P.A., Smith T.W., Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA. 90:1993;347-351.
22. Yasmin W., Strynadka K.D., Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res. 33:1997;422-432.
23. Romson J.L., Hook B.G., Kunkel S.L., Abrams G.D., Schork A., Lucchesi B.R. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation. 67:1983;1016-1023.
24. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1998;411-415.
25. Wei C.M., Lerman A., Rodeheffer R.J., McGregor C.G., Brandt R.R., Wright S., Heublein D.M., Kao P.C., Edwards W.D., Burnett J.C.J. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1586.
26. Kiowski W., Sutsch G., Hunziker P., Muller P., Kin J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
27. Dupuis J., Stewart D.J., Cernacek P., Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 94:1996;1578-1584.
28. Sakai S., Miyauchi T., Kobayashi M., Yamaguchi I., Goto K., Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 384:1996;353-355.
29. Pandey A.S., Stewardt D.J., Cernacek P., Dawood F., Wen W.H., Liu P. Chronic endothelin blockade preserves myocardial contractility in dilated cardiomyopathy. J Cardiovasc Pharmacol. 31:1998;S306-S308.
30. Haywood G.A., Tsao P.S., Von der Leyen H.E., Mann M.J., Keeling P.J., Trindade P.T., Lewis N.P. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 93:1996;1087-1094.
31. Liu P. The role of inducible nitric oxide synthase (iNOS) in myocaradial disease a functional duality . Lewis M.J., Shah A.J. Endothelial Modulation of Cardiac Function. 1997;91-102 Harwood Academic Publishers, London.
32. Lowenstein C.J., Snyder S.H. Nitric oxide, a novel biologic messenger. Cell. 70:1992;705-707.
33. McMurray J., Chopra M., Abdullah I., Smith W.E., Dargie H.J. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J. 14:1993;1493-1498.
34. Diaz-Velez C.R., Garcia Castineiras S., Mendoza-Ramos E., Hernandes-Lopez E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J. 131:1996;146-152.
35. Melino G., Bernassola F., Knight R.A., Corasaniti M.T., Nistico G., Finassi-Agro A. S-nitrosylation regulates apoptosis. Nature. 388:1997;432-433.
36. Uren N.G., Crake T., Lefroy D.C., de Silva R., Davies G.J., Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med. 331:1994;222-227.
37. Doi Y.L., Chikamori T., Tukata J., Yonezawa Y., Poloniecki J.D., Osawa T., McKenna W.J. Prognostic value of thallium-201 perfusion defects in idiopathic dilated cardiomyopathy. Am J Cardiol. 67:1991;188-193.
38. Tamai J., Nagata S., Nishimura T., Yutani C., Miyatake K., Sakakibara H., Nimura Y. Hemodynamic and prognostic value of thallium-201 myocardial imaging in patients with dilated cardiomyopathy. Int J Cardiol. 24:1989;219-224.